Indo Phyto Chemicals to expand its bulk drug unit in Shakanpur in Pirumadara

Details

Category: Bulk Drug Manufacturing

Indo Phyto Chemicals is to expand its bulk drug unit in Shakanpur in Pirumadara in Nainital in Uttarakhand with an investment of Rs. 50 million. The project involves expanding its bulk drug unit to produce Estradiol, Levonorgestrel, Norethisterone, Allylestrenol, Lynestrenol, Nandrolone Decanoate, ThiopentalSodium, Spironolactone, Solnaftate,Disulfiram etc., and will have a total capacity of 140000 kg /year .

Indo Phyto Chemicals Private Limited Village Shakhanpur, P.O. Pirumadara District Nainital, Uttarakhand- 244714. E-mail: [email protected]; Fax No.: 05947-282128; 282328

Infinity Laboratories to set up API unit in Behra

Details

Category: Bulk Drug Manufacturing

Infinity Laboratories Ltd to set up a active pharmaceuticals ingredient units in Behra village in Derabassi in Mohali district of Punjab. The project cost is estimated at Rs. 95 million and will produce Hydroxy phenyl glycine Dane Salt (478 tpa), Cefuroxime acid (66 tpa) and will produce sodium sulphate as by product (235 tpa).

Infinity Laboratories Private Limited H.No. 1080, Sector-12-A, Panchkula, Haryana E-mail: [email protected]

Astral Pharma receives USFDA approval for Vadodara plant

Details

Category: USFDA Approvals

Astral Pharma which manufactures sterile antibiotic powder injectables at Makrarpura in Vadodara in Gujarat has received USFDA approval, which facilitates the company to market its product in USA. The company has already received approvals from HPFBI-Canada, TGA-Australia, MCC-South Africa and ANVISA-Brazil. It has entered into strategic business tie up with Sagent Pharmaceutical Inc with whom more than 15 Abbreviated New Drug Application (ANDAs) have been filled for US market.  At Makarpura, the company has two manufacturing facilities- one for Semi Synthetic Penicillin group and other for cephlasporin group.

Dr.Reddy Laboratories to focus on domestic sales

Details

Category: Industry Overview

Dr.Reddy Laboratories which has been ranked 13th in terms of domestic sales is bringing its focus to improve its ranking. The company had been amongst the top ten few years back and lost it due to lack of focus. It plans to launch new therapeutic products in popular segments like cardiovascular, dermatology and diabetes and plans to strengthen its northern and eastern markets. The current Indian domestic market is estimated at Rs. 550,000 million and Dr.Reddys have a 2.7 % market share.